Last reviewed · How we verify
WX-081
At a glance
| Generic name | WX-081 |
|---|---|
| Sponsor | Shanghai Jiatan Pharmatech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients (PHASE3)
- Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults (PHASE1)
- Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects (PHASE1)
- Sudapyridine (WX-081) in Healthy Volunteers (PHASE1)
- Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WX-081 CI brief — competitive landscape report
- WX-081 updates RSS · CI watch RSS
- Shanghai Jiatan Pharmatech Co., Ltd portfolio CI